Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Vandetanib

056f3a9e-3979-59cc-9643-54b29fea2c16 · FDA Approved · targets KDR_VEGFR2

Vandetanib

MeasuredReference

Vandetanib targets EGFR, LCK, RET. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

EGFRLCKRETDDR2DDR1

Top hallmarks

  • tumor promoting inflammation4.3k
  • evading apoptosis3.8k
  • proliferation3.5k

Top pathways disrupted

  • apical junction10.2k
  • allograft rejection8.9k
  • pi3k akt mtor signaling8.6k

Resistance landscape — Vandetanib

MeasuredReference

10 known oncogenic variants exist on Vandetanib's top targets — see detail for inhibition impact.

Open in new tab